Advertisement

International Journal of Clinical Pharmacy

, Volume 40, Issue 1, pp 135–142 | Cite as

Efficacy and safety of atypical antipsychotics for behavioral symptoms of dementia among patients residing in long-term care

  • A. S. Sturm
  • K. E. Trinkley
  • K. Porter
  • Milap C. NahataEmail author
Research Article

Abstract

Background There are limited options for the treatment of behavioral and psychological symptoms of dementia (BPSD). Objective Evaluate the efficacy and safety of using atypical antipsychotics for BPSD among patients residing in long-term care. Setting Long term care community facility in the United States. Methods Retrospective observational study of patients residing in a long-term care facility with a diagnosis of dementia not trauma-induced with documented BPSD treated with an atypical antipsychotic for at least 2 weeks. Paper medical records were reviewed from January 1, 1990 until March 23, 2010. Main outcome measure Behavioral/psychological efficacy outcomes were documented beginning 2 weeks after atypical antipsychotic therapy was initiated and safety outcomes were documented from the time of atypical antipsychotic initiation, until the last documentation available. Efficacy and safety outcomes were documented as part of routine clinical practice based on the responsible clinician. Results A total of 85 distinct atypical antipsychotic treatment periods for 73 unique patients were included. Nearly 50% of patients continued atypical antipsychotic treatment for at least 1 year and 5.6% of treatments were discontinued due to an adverse event. Patients’ behavioral/psychological outcomes improved for 52 (61%) treatments, remained stable for 17 (20%) treatments, and worsened for 16 (19%) treatments. Adverse events were reported by 57% of patients, with the most common adverse events being metabolic, fall related, and extrapyramidal symptoms. The odds ratio for an adverse event was 1.08 (p = 0.03) for every 90 day increase in duration of treatment. Conclusion In patients who reside in a long-term care setting, atypical antipsychotic treatment improved BPSD, but also increased the potential risk of adverse events.

Keywords

Antipsychotics Dementia United States 

Notes

Funding

Supported in part by the Avatar Foundation, PDM Healthcare, 24700 Center Ridge Road, Suite 110, Cleveland, Ohio 44145, USA.

Conflicts of interest

No conflicts of interest have been declared.

References

  1. 1.
    Alzheimer’s Association. Alzheimer’s disease facts and figures. 2017. https://www.alz.org/documents_custom/2017-facts-and-figures.pdf. Accessed 15 Sept 2017.
  2. 2.
    Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010-2050) estimated using the 2010 census. Neurology. 2013;80:1778–83.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Rabins PV, Blacker D, Rovner BW, Rummans T, Schneider LS, Tariot PN, et al. American Psychiatric Association practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. Second edition. Am J Psychiatry. 2007;164:5–56.PubMedGoogle Scholar
  4. 4.
    Savva GM, Zaccai J, Matthews FE, Davidson JE, McKeith I, Brayne C. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry. 2009;194:212–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Cerejeira J, Lagarto L, Mukaetova-Ladinska EB. Behavioral and psychological symptoms of dementia. Front Neurol. 2012;7:73.Google Scholar
  6. 6.
    Ministry of Health. Best Practice Guideline for Accommodating and Managing Behavioral and Psychological Symptoms of Dementia in Residential Care. 2012. http://www.health.gov.bc.ca/library/publications/year/2012/bpsd-guideline.pdf. Accessed 15 Sept 2017.
  7. 7.
    Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer’s disease. Neurology. 1996;46:130–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Steinberg M, Lyketsos CG. Atypical antipsychotic use in patients with dementia: managing safety concerns. Am J Psychiatry. 2012;169:900–6.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Sansoni J, Anderson KH, Varona LM, Varela G. Caregivers of Alzheimer’s patients and factors influencing institutionalization of loved ones: some considerations on existing literature. Ann Ig. 2013;25:235–46.PubMedGoogle Scholar
  10. 10.
    Rabins PV, Mace NL, Jane LM. The impact of dementia on the family. JAMA. 1982;248:333–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Lin W-C, Tsai C-F, Wang S-J, Hwang J-P, Fuh J-L. Comparison of the burdens of family caregivers and foreign paid caregivers of the individuals with dementia. Int Psychogeriatr. 2012;24:1953–61.CrossRefPubMedGoogle Scholar
  12. 12.
    Ornstein K, Gaugler JE. The problem with “problem behaviors”: a systematic review of the association between individual patient behavioral and psychological symptoms and caregiver depression and burden within the dementia patient–caregiver dyad. Int Psychogeriatr. 2012;24:1536–52.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Mohamed S, Rosenheck R, Lyketsos CG, Kaczynski R, Sultzer DL, Schneider LS. Effect of second-generation antipsychotics on caregiver burden in Alzheimer’s disease. J Clin Psychiatry. 2012;73:121–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Meeks TW, Jeste DV. Beyond the black box: What is the role for antipsychotics in dementia? Curr Psychiatr. 2008;7:50–65.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Levy K, Lanctǒt KL, Farber SB, Li A, Herrmann N. Does pharmacological treatment of neuropsychiatric symptoms in Alzheimers disease relieve caregiver burden? Drugs Aging. 2012;29:167–79.CrossRefPubMedGoogle Scholar
  16. 16.
    Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934–43.CrossRefPubMedGoogle Scholar
  17. 17.
    Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized. Placebo-controlled trials. Am J Geriatr Psychiatry. 2006;14:191–210.CrossRefPubMedGoogle Scholar
  18. 18.
    Trifirò G, Spina E, Gambassi G. Use of antipsychotics in elderly patients with dementia: Do atypical and conventional agents have a similar safety profile? Pharmacol Res. 2009;59:1–12.CrossRefPubMedGoogle Scholar
  19. 19.
    Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, et al. Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease: Phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165:844–54.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Campanelli CM. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults: The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. J Am Geriatr Soc. 2012;60:616–31.CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Rabins PV, Lyketsos CG. Antipsychotic drugs in dementia: What should be made of the risks? JAMA. 2005;294:1963–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Centers for Medicare and Medicaid Services. Data show National Partnership to Improve Dementia Care exceeds goals to reduce unnecessary antipsychotic medications in nursing homes. 2014. https://www.leadingageil.org/portals/0/WeeksNews/2014/Sept14/Dementia care fact sheet 092314.pdf. Accessed 15 Sept 2017.
  23. 23.
    Center for Medicare Advocacy. CMA Report: Examining Inappropriate Use of Antipsychotic Drugs in Nursing Facilities. http://www.medicareadvocacy.org/cma-report-examining-inappropriate-use-of-antipsychotic-drugs-in-nursing-facilities/. Accessed 15 Sept 2017.
  24. 24.
    Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med. 2006;355:1525–38.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2017

Authors and Affiliations

  • A. S. Sturm
    • 1
  • K. E. Trinkley
    • 2
  • K. Porter
    • 3
  • Milap C. Nahata
    • 1
    • 4
    Email author
  1. 1.College of PharmacyOhio State UniversityColumbusUSA
  2. 2.Skaggs School of Pharmacy and Pharmaceutical Sciences and School of MedicineUniversity of ColoradoDenverUSA
  3. 3.Center for BiostatisticsOhio State UniversityColumbusUSA
  4. 4.Emeritus of Pharmacy, Pediatrics and Internal Medicine, Institute of Therapeutic Innovations and OutcomesOhio State UniversityColumbusUSA

Personalised recommendations